Abstract: Disclosed are plasmids that contain and express in vivo in a feline host cell nucleic acid molecules. The plasmid can include nucleic molecule(s) having sequence(s) encoding infectious peritonitis virus M; feline immunodeficiency virus env, or gag, or pro, or gag and pro, or env and gag and pro; rabies G; or feline leukemia virus env and/or gag. Compositions containing such plasmids, methods of use employing such plasmids, and kits involving such plasmids, are also disclosed.

Abstract: What is described is a recombinant vector, such as a virus; for instance, a poxvirus, such as avipox virus, containing foreign DNA from porcine reproductive and respiratory syndrome virus. What are also described are immunological compositions containing the recombinant poxvirus for inducing an immunological response in a host animal to which the immunological composition is administered. Also described are methods of treating or preventing disease caused by porcine reproductive and respiratory syndrome virus by administering the immunological compositions of the invention to an animal in need of treatment or susceptible to infection by porcine reproductive and respiratory syndrome virus.

Abstract: Disclosed and claimed are compositions for inducing in a bovine host an immunological response against bovine respiratory syncytial virus or bovine viral diarrhea virus containing at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine respiratory syncytial virus F protein, or G protein, or F and G proteins; or, at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine viral diarrhea virus E2 protein, or C, E1 and E2 proteins, or E1 and E2 proteins. Methods and kits employing such compositions are also disclosed.

Abstract: An avian plasmid vaccine contains a plasmid, and a pharmaceutically acceptable carrier. The plasmid contains and expresses in vivo in an avian host cell a nucleic acid molecule having a sequence encoding the Newcastle disease virus HN protein. The plasmid can further contain and express in vivo in an avian host cell a nucleic acid molecule having a sequence encoding the Newcastle disease virus F protein.

Abstract: Combination compositions including C. parvum antigen(s) or epitope(s) of interest with at least one other antigen or epitope of interest from a pathogen that causes enteric infection and/or symptoms and/or recombinant(s) and/or vector(s) and/or plasmid(s) expressing such antigen(s) or epitope(s) of interest and administration of such compositions such as to pregnant mammals and/or newborn or young mammals, for instance, pregnant cows and/or calves such as within the first month of birth, are disclosed and claimed.

Abstract: Disclosed and claimed are compositions for inducing in a bovine host an immunological response against bovine respiratory syncytial virus or bovine viral diarrhea virus containing at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine respiratory syncytial virus F protein, or G protein, or F and G proteins; or, at least one plasmid that contains and expresses in vivo in a bovine host cell nucleic acid molecule(s) having sequence(s) encoding bovine viral diarrhea virus E2 protein, or C, E1 and E2 proteins, or E1 and E2 proteins. Methods and kits employing such compositions are also disclosed.

Abstract: The avian vaccine formula comprises at least three polynucleotide vaccine valencies each comprising a plasmid integrating, so as to express it in vivo in the host cells, a gene with one avian pathogen valency, these valencies being selected from the group consisting of Marek's disease virus, Newcastle disease virus, infectious bursal disease virus, infectious bronchitis virus, infectious anaemia virus, the plasmids comprising, for each valency, one or more of the genes selected from the group consisting of gB and gD for the Marek's disease virus, HN and F for the Newcastle disease virus, VP2 for the infectious bursal disease virus, S, M and N for the infectious bronchitis virus, C+NS1 for the infectious anaemia virus.

Abstract: Disclosed are plasmids that contain and express in vivo in a feline host cell nucleic acid molecules. The plasmid can include nucleic molecule(s) having sequence(s) encoding infectious peritonitis virus M; feline immunodeficiency virus env, or gag, or pro, or gag and pro, or env and gag and pro; rabies G; or feline leukemia virus env and/or gag. Compositions containing such plasmids, methods of use employing such plasmids, and kits involving such plasmids, are also disclosed.

Abstract: The avian recombinant live vaccine comprises, as vector, an ILTV virus comprising and expressing at least one heterologous nucleotide sequence, this nucleotide sequence being inserted into the insertion locus formed by the intergenic region situated between the stop codons of the ORF D and ORF E of ILTV and which, in a specific ILTV strain, is defined between nucleotides 3873 and 4260 in SEQ ID No:1. The heterologous nucleotide sequence may be under the control of a strong eukaryotic promoter, such as the CMV-IE promoter, and may be derived from the Newcastle disease virus, Marek's disease virus, the infectious bursal disease virus, the infectious bronchitis virus, the chicken anaemia virus and the chicken pneumovirosis virus. Multivalent vaccine formula comprising at least two live vaccines according to the invention. ILTV virus thus recombined.

Abstract: Disclosed is an immunological or vaccine composition that includes at least one plasmid that contains and expresses in vivo in host canine cells a nucleic acid molecule that encodes an antigen of a canine pathogen, such as rabies G. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.

Abstract: Disclosed is an immunological composition that includes at least two plasmids; each plasmid contains and expresses in vivo in host canine cells a nucleic acid molecule that encodes an antigen of a canine pathogen. The plasmids can include more than one nucleic acid molecule such that the plasmids can express more than one antigen. The composition can include a first plasmid that contains and expresses a nucleic acid molecule encoding canine parvovirus VP2 and a second plasmid that contain(s) and express(es) nucleic acid molecule(s) encoding canine distemper HA and/or F.

Abstract: The avian vaccine formula comprises at least three polynucleotide vaccine valencies each comprising a plasmid integrating, so as to express it in vivo in the host cells, a gene with one avian pathogen valency, these valencies being selected from the group consisting of Marek's disease virus, Newcastle disease virus, infectious bursal disease virus, infectious bronchitis virus, infectious anaemia virus, the plasmids comprising, for each valency, one or more of the genes selected from the group consisting of gB and gD for the Marek's disease virus, HN and F for the Newcastle disease virus, VP2 for the infectious bursal disease virus, S, M and N for the infectious bronchitis virus, C+NS1 for the infectious anaemia virus.

Abstract: The present invention relates to a vaccine formula allowing in particular the vaccination of pigs against reproductive and respiratory pathologies. It also relates to a corresponding method of vaccination.

Abstract: Disclosed and claimed is: an immunogenic or vaccine composition for inducing in an equine host an immunological response against equine rhinopneumonitis virus (EHV) containing at least one plasmid that contains and expresses in vivo in an equine host cell nucleic acid molecule(s) having sequence(s) encoding EHV gB, gD, or gB and gD; an immunogenic or vaccine composition for inducing in an equine host immunological response against encephalomyelitis virus containing at least one plasmid that contains and expresses in vivo in an equine host cell nucleic acid molecule(s) having sequence(s) encoding encephalomyelitis virus C, E2, or C and E2 proteins; and, methods for using and kits employing such compositions.

Abstract: Disclosed and claimed is a recombinant canine herepes virus (CHV). The recombinant CHV includes and expresses at least one heterologous nucleotide sequence encoding an antigen. The antigen can be canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, or Borrelia burgdorferi OspB. The at least one heterologous nucleotide sequence can be in at least one insertion site selected from the group consisting of ORF3 (SEQ ID NO:4), ORF5 (SEQ ID NO:5), the thymidine kinase gene, and the intergenic region corresponding to genes coding for the large subunit and the small subunit. Immunological or vaccine compositions as well as methods for inducing an immunological response are also disclosed and claimed.

Abstract: The living recombinant avian vaccine comprises, as a vector, an ILTV virus comprising and expressing at least one heterologous nucleotide sequence, this nucleotide sequence being inserted in the insertion locus defined between the nucleotides 1624 and 3606 at the SEQ ID NO: 5. The vaccine may in particular comprise a sequence coding for an antigen of an avian pathogenic agent selected among the group consisting of the Newcastle disease virus (NDV), the infections bursal virus (IBDV), the Marek disease virus (MDV), the infectious bronchitis virus (IBV), the chicken anaemia virus (CAV), thee chicken pneumovirosis virus, preferably under the control of a strong eukariotic promoter. A multivalent vaccine formula is also disclosed.

Abstract: The invention comprises the nucleotide sequences comprising the FIPV S gene, or a fragment of this gene, which are modified in at least one of the antigenic regions A1 and A2 which are involved in enhancement, as well as the use of these sequences for the expression of modified proteins, and for the construction of recombinant viruses or expression plasmids, and the use of the recombinant viruses as vaccines against feline infectious peritonitis, the use of the expression plasmids as immunizing composition by direct injection of the said plasmids into cats, and the use of the modified proteins as vaccine.